RBC sees over 80% upside to its price target for this medical stock
Investing.com -- RBC Capital Markets reaffirmed its bullish stance on this stock after the diabetes technology company delivered stronger-than-expected first-quarter ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
